International Prostate Symptom Score (IPSS) for Initial Assessment of BPH

IPSS Assessment Components

The American Urological Association (AUA) recommends using the AUA Symptom Index, which is identical to the seven symptom questions of the International Prostate Symptom Score (IPSS), as the symptom-scoring instrument in the initial assessment of each patient presenting with suspected Benign Prostatic Hyperplasia (BPH) 1, 2, 3
The IPSS consists of seven questions that assess both irritative symptoms (frequency, urgency, nocturia) and obstructive symptoms (incomplete emptying, stopping and starting, weak stream, pushing or straining) 1, 4
The IPSS includes a Disease Specific Quality of Life (QoL) question that measures how bothered the patient is by their urinary symptoms 2, 4

IPSS is superior to an unstructured interview in quantifying symptom frequency and severity 1
The tool has been validated for clarity, test/retest reliability, internal consistency, and criteria strength 1

For patients with moderate symptoms (IPSS 8-19), the AUA recommends alpha-blockers with evaluation at 1 and 3 months for those with small prostate, and alpha-blockers or 5-alpha reductase inhibitors with evaluation at 3 and 6 months for those with large prostate (>30cc) 5

The AUA recommends first follow-up visit should be scheduled 4-12 weeks after initiating alpha blockers, PDE5 inhibitors, anticholinergics, or beta-3 agonists 6, 5
For 5-alpha reductase inhibitors, first follow-up should be at 3-6 months due to longer onset of action 6, 5
IPSS should be readministered at each follow-up visit to objectively assess symptom changes 6

Relying solely on IPSS without considering the patient's bother level - an intervention may be more appropriate for a moderately symptomatic patient who is bothered than for a severely symptomatic patient who is not bothered 1, 2
Failing to explain the questions to patients who may not fully understand the intent of the questionnaire 1
Using IPSS as a replacement for personal discussion of symptoms with the patient 1

In men with moderate benign prostatic hyperplasia symptoms, treatment with alpha‑blockers (e.g., doxazosin, terazosin, tamsulosin, alfuzosin) produces an average decrease of 2.1 – 3.7 points on the International Prostate Symptom Score. 7

In men with moderate symptoms and larger prostate volumes, 5‑alpha reductase inhibitors (e.g., finasteride, dutasteride) lower the IPSS by an average of 1.35 – 1.82 points, with noticeable effects typically emerging after 3 – 6 months of therapy. 7